About CardioMag

CardioMag Imaging, Inc. (CMI) is a privately held medical device company founded in 1999 and is engaged in the development and commercialization of a unique kind of cardiac diagnostic device known as MagnetoCardioGraphs (MCG). The device the company has developed consists of the integration of highly sophisticated proprietary sensors, electronics, and software.

The company’s MCG system is a non-invasive cardiac medical diagnostic device that provides unique and clinically relevant information about heart function without use of ionizing radiation. CardioMag’s MCG system is the world's first and only MCG system to obtain FDA approval. The basis of the device relies on analyzing magnetic fields generated by the heart’s electrical activity, as such, it can be applied broadly, from prevention, through diagnosis, to determine the relative risk of cardiac rehabilitation. From the MCG analysis of ventricular repolarization alone, the physician can tell whether a patient has underlying coronary artery disease and -- using beat-to-beat analysis - the relative risk of sudden cardiac death.

Recent clinical research suggests that MCG has the diagnostic power of nuclear imaging techniques such as Single Photon Emission Computed Tomography (SPECT), but without the use of ionizing radiation and without submitting the patient to physical or pharmacologically induced stress.